Related references
Note: Only part of the references are listed.CHRAC1 promotes human lung cancer growth through regulating YAP transcriptional activity
Mingwei Wang et al.
CARCINOGENESIS (2021)
Hippo Signaling Pathway in Gliomas
Konstantin Masliantsev et al.
CELLS (2021)
Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma
Jacquelyn T. Saunders et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Targeting cell-cycle machinery in cancer
Jan M. Suski et al.
CANCER CELL (2021)
YAP promotes autophagy and progression of gliomas via upregulating HMGB1
Min Zhao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Jacob P. Fisher et al.
BIOMEDICINES (2021)
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity
Joel D. Pearson et al.
CANCER CELL (2021)
Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide
Yan Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme
Sai Qiao et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
Lindsey R. Pack et al.
NATURE COMMUNICATIONS (2021)
Biosynthesis and heterologous production of furanocoumarins: perspectives and current challenges
Joana L. Rodrigues et al.
NATURAL PRODUCT REPORTS (2021)
YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma
Krishanthan Vigneswaran et al.
CLINICAL CANCER RESEARCH (2021)
Recent Advances of the Hippo/YAP Signaling Pathway in Brain Development and Glioma
Taohui Ouyang et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2020)
YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy
Barry J. Thompson
BIOESSAYS (2020)
The Science and (Lost) Art of Psoralen Plus UVA Phototherapy
Elisabeth G. Richard
DERMATOLOGIC CLINICS (2020)
YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators
Sany Hoxha et al.
CANCER RESEARCH (2020)
Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review
Jie Li et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)
Angelicin-A Furocoumarin Compound With Vast Biological Potential
Camille Keisha Mahendra et al.
FRONTIERS IN PHARMACOLOGY (2020)
In Silico Studies and In Vivo MAOA Inhibitory Activity of Coumarins Isolated from Angelica archangelica Extract: An Approach toward Antidepressant Activity
Anudeep Kaur et al.
ACS OMEGA (2020)
Molecular targeted therapy of glioblastoma
Emilie Le Rhun et al.
CANCER TREATMENT REVIEWS (2019)
The Hippo Pathway: Biology and Pathophysiology
Shenghong Ma et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
PR55α regulatory subunit of PP2A inhibits the MOB1/LATS cascade and activates YAP in pancreatic cancer cells
Ashley L. Hein et al.
ONCOGENESIS (2019)
Glioma epigenetics: From subclassification to novel treatment options
Olga Gusyatiner et al.
SEMINARS IN CANCER BIOLOGY (2018)
YAP promotes breast cancer metastasis by repressing growth differentiation factor-15
Ting Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity
Xuesong Yuan et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
YAP Promotes Migration and Invasion of Human Glioma Cells
Yu Zhang et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2018)
Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ
Jianxiong Ji et al.
CELL DEATH & DISEASE (2018)
Cell-Cycle Therapeutics Come of Age
Matthew Ingham et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
β-catenin-mediated YAP signaling promotes human glioma growth
Yan Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas
Mei Liu et al.
LABORATORY INVESTIGATION (2017)
Angelicin inhibits liver cancer growth in vitro and in vivo
Fengliang Wang et al.
MOLECULAR MEDICINE REPORTS (2017)
Roles for RACK1 in cancer cell migration and invasion
Deirdre Duff et al.
CELLULAR SIGNALLING (2017)
Angelicin inhibits human lung carcinoma A549 cell growth and migration through regulating JNK and ERK pathways
Guangcai Li et al.
ONCOLOGY REPORTS (2016)
Tead and AP1 Coordinate Transcription and Motility
Xiangfan Liu et al.
CELL REPORTS (2016)
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Francesca Zanconato et al.
NATURE CELL BIOLOGY (2015)
Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability
Qi Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Antiviral activity of angelicin against gammaherpesviruses
Hye-Jeong Cho et al.
ANTIVIRAL RESEARCH (2013)
Angelicin regulates LPS-induced inflammation via inhibiting MAPK/NF-κB pathways
Fang Liu et al.
JOURNAL OF SURGICAL RESEARCH (2013)
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Fa-Xing Yu et al.
CELL (2012)
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain
John M. Lamar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF beta-TRCP
Bin Zhao et al.
GENES & DEVELOPMENT (2010)
Elucidation of a universal size-control mechanism in Drosophila and mammals
Jixin Dong et al.
CELL (2007)
Share Paper
